Premium
A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T‐cell lymphoma
Author(s) -
Scarisbrick J.J.,
Child F.J.,
Clift A.,
Sabroe R.,
Whittaker S.J.,
Spittle M.,
RussellJones R.
Publication year - 2001
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.2001.04191.x
Subject(s) - fludarabine , medicine , cyclophosphamide , chemotherapy , bone marrow , lymphoma , regimen , mycosis fungoides , refractory (planetary science) , surgery , gastroenterology , oncology , progressive disease , physics , astrobiology
Background The combination of fludarabine and cyclophosphamide shows synergistic toxicity in vitro and has been used to treat nodal non‐Hodgkin’s lymphoma and relapsed chronic lymphocytic leukaemia. Objectives To test the efficacy of this combination in 12 patients with cutaneous T‐cell lymphoma (CTCL). Methods Nine patients with erythrodermic CTCL were identified for the study, eight of whom met the criteria for Sézary syndrome (SS), and three with tumour‐stage mycosis fungoides (MF). Patients received intravenous fludarabine and cyclophosphamide 3 days monthly for 3–6 months. Results Six patients tolerated at least three cycles. Five with SS had a response (one had a complete clinical response and four a partial response) and one patient with MF had stable disease. The mean duration of the response was 10 months. Six patients had treatment withdrawn, five due to bone marrow suppression and one due to progressive disease. No difference in pretrial parameters were found in those who had treatment withdrawn and those who tolerated at least three courses. Survival since the trial was similar in both groups at 11 months. Conclusions These data indicate that the combination of fludarabine with cyclophosphamide may be of clinical benefit in patients with SS but does not affect patient survival. As with other multiagent chemotherapy regimens, bone marrow toxicity is a common and severe side‐effect. These data suggest that this regimen should be considered palliative and should be reserved for patients with refractory disease without bone marrow suppression.